In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vesper Medical raises $37mm in second funding round

Executive Summary

Vesper Medical Inc. (devices for minimally invasive peripheral vascular procedures) raised $37mm in what appears to be its Series B financing led by Vensana Capital and Gilde Healthcare, which were joined by returning shareholders New Enterprise Associates and Quaker Partners. The company expects to receive funding from additional tranches based on key milestones. Vesper will use the proceeds to finish developing its Duo venous stent system and submit the PMA application to the FDA. Additional money will help gain the CE Mark for Vesper Duo stents. On the same day, Intact Vascular Inc., which spun out Vesper and is also developing minimally invasive devices for peripheral vascular procedures, raised $25mm through its Series D financing in which Vensana, NEA, and Quaker also participated.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies